When we examined the underlying mechanism by which Ler overcomes the resistance of cancer cells to Btz, we found that Ler co-treatment markedly enhanced Btz-induced increases in poly-ubiquitinated protein accumulation, PERK and eIF2α phosphorylation, and ATF4 and CHOP levels. The gene discussed is CASC3; the disease is cancer.